Molecular Docking and Screening Studies of New Natural Sortase A Inhibitors
- PMID: 29065551
- PMCID: PMC5666896
- DOI: 10.3390/ijms18102217
Molecular Docking and Screening Studies of New Natural Sortase A Inhibitors
Abstract
To date, multi-drug resistant bacteria represent an increasing health threat, with a high impact on mortality, morbidity, and health costs on a global scale. The ability of bacteria to rapidly and permanently acquire new virulence factors and drug-resistance elements requires the development of new antimicrobial agents and selection of new proper targets, such as sortase A. This specific bacterial target plays an important role in the virulence of many Gram-positive pathogens, and its inhibition should produce a mild evolutionary pressure which will not favor the development of resistance. A primary screening using a fluorescence resonance energy transfer assay was used to experimentally evaluate the inhibitory activity of several compounds on sortase A. Using molecular docking and structure-activity relationship analyses, several lead inhibitors were identified, which were further tested for antimicrobial activity using the well diffusion test and minimum inhibitory concentration. The toxicity was assessed using the Daphnia magna test and used as a future screening filter. Three natural compounds were identified in this study as promising candidates for further development into therapeutically useful anti-infective agents that could be used to treat infections caused by multi-drug resistant bacterial pathogens which include sortase A in their enzymatic set.
Keywords: Daphnia magna; Gram-positive bacteria; MDR-bacteria; Staphylococcus aureus; anti-infective; molecular docking; sortase A.
Conflict of interest statement
The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.
Figures










Similar articles
-
Sortase A: an ideal target for anti-virulence drug development.Microb Pathog. 2014 Dec;77:105-12. doi: 10.1016/j.micpath.2014.10.007. Epub 2014 Oct 18. Microb Pathog. 2014. PMID: 25457798 Review.
-
Optimized protocols for assessing libraries of poorly soluble sortase A inhibitors for antibacterial activity against medically-relevant bacteria, toxicity and enzyme inhibition.Bioorg Med Chem. 2021 Dec 15;52:116527. doi: 10.1016/j.bmc.2021.116527. Epub 2021 Nov 20. Bioorg Med Chem. 2021. PMID: 34839159
-
Discovery of natural naphthoquinones as sortase A inhibitors and potential anti-infective solutions against Staphylococcus aureus.Drug Dev Res. 2019 Dec;80(8):1136-1145. doi: 10.1002/ddr.21599. Epub 2019 Sep 4. Drug Dev Res. 2019. PMID: 31486108
-
Discovery and structure-activity relationship studies of irreversible benzisothiazolinone-based inhibitors against Staphylococcus aureus sortase A transpeptidase.Bioorg Med Chem. 2014 Nov 1;22(21):5988-6003. doi: 10.1016/j.bmc.2014.09.011. Epub 2014 Sep 16. Bioorg Med Chem. 2014. PMID: 25282649
-
Sortase as a target of anti-infective therapy.Pharmacol Rev. 2008 Mar;60(1):128-41. doi: 10.1124/pr.107.07110. Epub 2008 Mar 5. Pharmacol Rev. 2008. PMID: 18321961 Review.
Cited by
-
A Rhein-Based Derivative Targets Staphylococcus aureus.Antibiotics (Basel). 2024 Sep 13;13(9):882. doi: 10.3390/antibiotics13090882. Antibiotics (Basel). 2024. PMID: 39335055 Free PMC article.
-
Synthesis and Toxicity Evaluation of New Pyrroles Obtained by the Reaction of Activated Alkynes with 1-Methyl-3-(cyanomethyl)benzimidazolium Bromide.Molecules. 2021 Oct 25;26(21):6435. doi: 10.3390/molecules26216435. Molecules. 2021. PMID: 34770844 Free PMC article.
-
In-Silico Identified New Natural Sortase A Inhibitors Disrupt S. aureus Biofilm Formation.Int J Mol Sci. 2020 Nov 14;21(22):8601. doi: 10.3390/ijms21228601. Int J Mol Sci. 2020. PMID: 33202690 Free PMC article.
-
The application of mesoporous silica nanoparticles as a drug delivery vehicle in oral disease treatment.Front Cell Infect Microbiol. 2023 Feb 14;13:1124411. doi: 10.3389/fcimb.2023.1124411. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 36864881 Free PMC article. Review.
-
Myricetin Acts as an Inhibitor of Type II NADH Dehydrogenase from Staphylococcus aureus.Molecules. 2024 May 16;29(10):2354. doi: 10.3390/molecules29102354. Molecules. 2024. PMID: 38792214 Free PMC article.
References
-
- The World Health Organization (WHO) WHO Publishes List of Bacteria for Which New Antibiotics are Urgently Needed. WHO; Geneva, Switzerland: 2017.
-
- Zhang Y., Zhang J., Chen W., Angsantikul P., Spiekermann K.A., Fang R.H., Gao W., Zhang L. Erythrocyte membrane-coated nanogel for combinatorial antivirulence and responsive antimicrobial delivery against Staphylococcus aureus infection. J. Control. Release. 2017;263:185–191. doi: 10.1016/j.jconrel.2017.01.016. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases